Overview

Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy

Status:
Suspended

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

Open label, nonrandomized, dose-escalation with cohort expansion trial of MVT-5873/MVT-1075 in subjects with previously treated, CA19-9 positive malignancies (e.g., pancreatic adenocarcinoma).

Phase:

Phase 1

Details

Lead Sponsor:

BioNTech Research & Development, Inc.
MabVax Therapeutics, Inc.

Treatments:

Antibodies
Antibodies, Monoclonal